Anthrax Vaccine Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 5.98 Billion |
| Market Size (2030) | USD 9.13 Billion |
| Growth Rate (2025 - 2030) | 7.30% CAGR |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Anthrax Vaccine Market Analysis by Mordor Intelligence
The anthrax vaccine market is valued at USD 5.98 billion in 2025 and is forecast to reach USD 9.13 billion by 2030, advancing at a 7.30% CAGR. Demand holds firm as national stockpiling programs allocate multi-year budgets, exemplified by the United States’ USD 79.5 billion PHEMCE plan that assigns USD 1.3 billion to CYFENDUS procurement[1]Source: Innovation, Science and Economic Development Canada, “Federal government launches Health Emergency Readiness Canada,” canada.ca. Military vaccination mandates, such as the Department of Defense’s USD 235.8 million BioThrax agreement through 2033, secure predictable offtake. Regulatory momentum continues with FDA approval of CYFENDUS and South Korea’s clearance of the recombinant GC-1109 vaccine, signaling broader acceptance of next-generation formulations. Manufacturing investments, including the USD 2 billion BioMaP-Consortium, aim to diversify supply amid facility realignments by incumbents. Geopolitical tensions keep the threat of bioterrorism in policy focus, translating into steady requisitions across allied regions.
Key Report Takeaways
- By vaccine type, Cell-free Anthrax Vaccine Adsorbed led with 48.67% of anthrax vaccine market share in 2024; Adjuvanted AV7909 is projected to grow at an 8.35% CAGR to 2030.
- By end user, the Military & Defense segment held 55.45% of the anthrax vaccine market size in 2024, while Government Civilian Agencies expand fastest at 8.71% CAGR through 2030.
- By application, Pre-Exposure prophylaxis accounted for 60.23% of the anthrax vaccine market size in 2024 and is forecast to advance at a 7.9% CAGR to 2030.
- By geography, North America dominated with 58.45% anthrax vaccine market share in 2024; Asia-Pacific is poised for the highest regional CAGR at 9.87% to 2030.
Global Anthrax Vaccine Market Trends and Insights
Driver Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Government biodefense stockpiling budgets increasing post-COVID | +2.1% | Global, with concentration in North America & EU | Medium term (2-4 years) |
| Mandatory vaccination programs for military & high-risk lab personnel | +1.8% | Global, led by North America, expanding to APAC | Long term (≥ 4 years) |
| Regulatory approvals of next-generation vaccines (e.g., CYFENDUS) | +1.5% | North America & EU primary, APAC emerging | Short term (≤ 2 years) |
| Rising geopolitical bioterrorism threat perception globally | +1.2% | Global, with regional hotspots in APAC & MEA | Long term (≥ 4 years) |
| Thermostable dry-powder vaccines enabling LMIC procurement | +0.9% | APAC, MEA, Latin America | Medium term (2-4 years) |
| Synthetic-biology platforms cutting cost & lead-time | +0.7% | Global, with early adoption in North America & EU | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Government Biodefense Stockpiling Budgets Increasing Post-COVID
National budgets reclassified anthrax countermeasures as core security assets. The U.S. Strategic National Stockpile expanded multi-year contracts, including a USD 250 million modification covering CYFENDUS, highlighting lessons from pandemic supply bottlenecks. Canada’s Health Emergency Readiness Canada initiative adds regional alignment with domestic manufacturing capacity[2]Source: U.S. Department of Health and Human Services, “PHEMCE Multiyear Budget: Fiscal Years 2023–2027,” aspr.hhs.gov. Defense Threat Reduction Agency grants of USD 26.3 million sustain R&D pipelines, ensuring that the anthrax vaccine market remains integrated into broader chemical–biological defense funding.
Mandatory Vaccination Programs for Military & High-Risk Lab Personnel
Compulsory protocols broaden beyond troops to laboratory and emergency response staff, reinforcing the anthrax vaccine market in established buying centers. The CDC’s 2023 guideline update enlarges the eligible workforce, while an FDA-approved five-dose schedule improves adherence logistics. NATO interoperability standards likewise push adoption across allied forces.
Regulatory Approvals of Next-Generation Vaccines (e.g., CYFENDUS)
The FDA’s 2023 clearance of CYFENDUS validated fast-acting adjuvanted formulations with a two-dose post-exposure protocol. South Korea’s 2025 approval of recombinant GC-1109 underscores global regulatory receptivity to synthetic biology platforms. BARDA’s Target Product Profiles now prioritize single-dose efficacy, incentivizing R&D toward simplified regimens.
Rising Geopolitical Bioterrorism Threat Perception Globally
Regional security briefs cite potential weaponization of Bacillus anthracis, prompting increased procurement. South Korea’s readiness plans against North Korean capabilities and U.S. intelligence on dual-use biotech in China illustrate the strategic value placed on rapid-response vaccines.
Restraint Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Adverse-event profile & litigation risk limits civilian uptake | -1.4% | Global, with highest impact in North America & EU | Medium term (2-4 years) |
| Dependence on a single dominant supplier creates supply risk | -0.8% | Global, with critical exposure in North America | Short term (≤ 2 years) |
| Limited commercial demand outside government contracts | -0.6% | Global, with concentration in developed markets | Long term (≥ 4 years) |
| Emerging mAb & small-molecule alternatives divert funding | -0.4% | North America & EU primary, expanding globally | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Adverse-Event Profile & Litigation Risk Limits Civilian Uptake
Injection-site reactions and past legal disputes dampen broad-based demand. Civilian insurers seldom reimburse preventive doses, and no pediatric indication exists, narrowing the anthrax vaccine market beyond government channels.
Dependence on a Single Dominant Supplier Creates Supply Risk
Emergent BioSolutions’ facility closures in 2024 exposed fragility in an almost single-supplier ecosystem, prompting governments to hedge through recombinant and contract-manufacture alternatives
Segment Analysis
By Vaccine Type: Cell-Free Dominance Faces Adjuvanted Challenge
Cell-free formulations commanded 48.67% anthrax vaccine market share in 2024 as longstanding familiarity drove procurement. Adjuvanted AV7909, led by CYFENDUS, grows at 8.35% CAGR on faster seroconversion that meets emergency timelines. Manufacturing strategies pivot toward recombinant antigens, evidenced by GC-1109’s licensure, easing biosafety constraints inherent in culture-based production. Patent filings for thermostable spray-dried doses aim to remove cold-chain costs and widen reach in low-resource markets.
A future pipeline that includes mRNA and viral-vector concepts remains preclinical but could disrupt the anthrax vaccine industry if single-dose efficacy targets are met. Cross-sector lessons from COVID-19 have validated adjuvant dose-sparing frameworks, likely accelerating platform diversification.
By End User: Military Dominance Yields to Civilian Growth
Military & Defense held 55.45% of the anthrax vaccine market size in 2024, anchored by locked-in contracts and deployment protocols. Civilian agencies expand at 8.71% CAGR, propelled by CDC guidance encompassing lab workers and first responders. Veterinary and One Health programs grow where endemic livestock outbreaks occur, linking animal health budgets to human countermeasure funding.
International collaborations, such as India’s BioThrax partnership with Biological E., bring supply closer to regional civilian buyers, easing import reliance and raising baseline demand across South Asia investors.emergentbiosolutions.com. Research institutions also raise call-off volumes to satisfy biosafety clearances for anthrax-related experimentation.
By Application: Pre-Exposure Protocols Drive Current Demand
Pre-Exposure vaccination secured 60.23% of the anthrax vaccine market size in 2024 on embedded military schedules. Post-Exposure demand accelerates at 9.08% CAGR as CYFENDUS enables two-dose prophylaxis, meeting BARDA’s rapid-response benchmarks. Integrated stockpile strategies purchase both antibiotics and vaccines, creating bundled contracts that reward suppliers with diversified portfolios.
Therapeutic applications stay exploratory. However, synthetic biology efforts hint at dual-action constructs that might blur the line between prophylaxis and treatment, expanding future addressable volumes for the anthrax vaccine market.
By Distribution Channel: Direct Procurement Maintains Control
Direct Government Procurement accounted for 69.67% market share in 2024 as security protocols dictate centralized buying. Allied nations increasingly arrange direct-order agreements under mutual-defense frameworks, giving Direct Order Suppliers a 9.47% CAGR outlook. Commercial pharmacy distribution remains negligible except under emergency use authorizations, reflecting controlled-substance status of biodefense countermeasures.
Facility realignments have inspired interest in multi-site contract manufacturing; Scorpius BioManufacturing’s plan to produce Anthim antitoxin in Kansas signals emerging redundancy in the supply chain.
Geography Analysis
North America retained 58.45% anthrax vaccine market share in 2024, supported by the Strategic National Stockpile’s rolling replenishments and consistent FDA approvals. A USD 2 billion domestic manufacturing drive under the BioMaP-Consortium strengthens regional self-reliance, while Canada’s HERC program aligns cross-border capacity.
Asia-Pacific posts the fastest CAGR at 9.87% to 2030. South Korea’s GC-1109 breakthrough and India’s BioThrax approval embed local production, diminishing sole dependence on U.S. supply and amplifying regional orders. Thailand’s 2025 anthrax outbreak response highlighted the urgency for wider livestock and human vaccine availability, prompting ASEAN regulators to discuss harmonized fast-track pathways.
Europe sustains moderate growth as the EU’s Health Technology Assessment Regulation targets synchronized member-state decisions on critical vaccines. Recent African outbreaks drive donor-funded procurements, although constrained budgets limit immediate volume. Latin American interest rises slowly, awaiting structured financing mechanisms that could tap into regional development banks.
Competitive Landscape
The anthrax vaccine market remains concentrated. Emergent BioSolutions controls the only two FDA-licensed vaccines, but facility closures and 2024 revenue volatility reveal operational risk. Its USD 9 million acquisition of raxibacumab monoclonal antibody, underpinned by a USD 130 million BARDA contract, reinforces portfolio breadth.
Challengers leverage synthetic biology. GC Biopharma entered the market with a recombinant vaccine, while iBio applies AI-guided antibody design to accelerate pipeline candidates. Contract manufacturing partnerships, such as Scorpius BioManufacturing’s Anthim arrangement, diversify source options beyond traditional incumbents.
Patent filings for IL-33 adjuvant systems, thermostable formulations, and spray-drying techniques suggest a pipeline pivot toward shelf-stable products suitable for global south logistics uspto.report. Government buyers continue to reward readiness, yet supplier diversification is likely as regulators approve more platforms and national security policies prioritize redundancy.
Anthrax Vaccine Industry Leaders
-
Colondo Serum Company
-
Merck Co, Inc. (MSD Animal Health)
-
Emergent BioSolutions Inc.
-
Proton Biopharma Ltd
-
Altimmune (Pharmathene Inc.)
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- April 2025: South Korea’s MFDS approved Barythrax (GC-1109), the first recombinant anthrax vaccine, co-developed by GC Biopharma and KDCA.
- March 2025: Emergent BioSolutions secured USD 250 million in BARDA contract modifications covering CYFENDUS supply for the Strategic National Stockpile
Global Anthrax Vaccine Market Report Scope
Anthrax is an infectious disease caused by gram-positive, rod-shaped bacteria called Bacillus anthracis. It is a rare but serious infection and may affect both animals and humans. Humans and animals get infected when spores enter their bodies through inhalation, contaminated food, soil, cut, or scrape in the skin.
The anthrax vaccine market is segmented by vaccine type (cell-free PA vaccine and live attenuated vaccine), application type (animal use and human use), distribution channel (hospitals, pharmacies, and other distribution channels), and geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD) for the above segments.
| Cell-free Anthrax Vaccine Adsorbed (AVA) |
| Adjuvanted Anthrax Vaccine (AV7909/CYFENDUS) |
| Recombinant Protective Antigen Vaccine |
| Others |
| Military & Defense |
| Government Civilian Agencies |
| Healthcare Workers & First Responders |
| Veterinary Sector |
| General Population High-risk Travelers |
| Pre-Exposure Prophylaxis |
| Post-Exposure Prophylaxis |
| Direct Government Procurement |
| Hospital & Clinic Pharmacies |
| Direct Order Suppliers |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| India | |
| Japan | |
| South Korea | |
| Australia | |
| Rest of Asia-Pacific | |
| South America | Brazil |
| Argentina | |
| Rest of South America | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa |
| By Vaccine Type (Value) | Cell-free Anthrax Vaccine Adsorbed (AVA) | |
| Adjuvanted Anthrax Vaccine (AV7909/CYFENDUS) | ||
| Recombinant Protective Antigen Vaccine | ||
| Others | ||
| By End User (Value) | Military & Defense | |
| Government Civilian Agencies | ||
| Healthcare Workers & First Responders | ||
| Veterinary Sector | ||
| General Population High-risk Travelers | ||
| By Application (Value) | Pre-Exposure Prophylaxis | |
| Post-Exposure Prophylaxis | ||
| By Distribution Channel (Value) | Direct Government Procurement | |
| Hospital & Clinic Pharmacies | ||
| Direct Order Suppliers | ||
| By Geography (Value) | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| India | ||
| Japan | ||
| South Korea | ||
| Australia | ||
| Rest of Asia-Pacific | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
Key Questions Answered in the Report
What is the current Global Anthrax Vaccine Market size?
The Global Anthrax Vaccine Market is projected to register a CAGR of 7.6% during the forecast period (2025-2030)
What is the current value of the anthrax vaccine market?
The anthrax vaccine market stands at USD 5.98 billion in 2025 and is projected to reach USD 9.13 billion by 2030.
Which region leads the anthrax vaccine market?
North America holds 58.45% market share in 2024 due to Strategic National Stockpile purchases and recent FDA approvals.
Which vaccine type is growing fastest?
Adjuvanted AV7909, driven by CYFENDUS, posts an 8.35% CAGR for 2025-2030.
Why are civilian agencies becoming important buyers?
Expanded CDC guidelines now include lab workers and first responders, pushing Government Civilian Agencies to the fastest growth rate at 8.71% CAGR.
Page last updated on:
